All Stories

  1. Association of serum magnesium levels and calcimimetic use: fractures and cardiovascular events in Japanese haemodialysis patients

    Article • Journal of Bone and Mineral Metabolism, February 2026, Springer Science + Business Media

    Professor Hiroaki Ogata

  2. Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study

    Article • Hypertension Research, January 2026, Springer Science + Business Media

    Professor Hiroaki Ogata, Jun Wada

  3. Undiagnosed Coronary Artery Disease in Hemodialysis-Initiating Patients

    Article • Journal of Atherosclerosis and Thrombosis, December 2025, Japan Atherosclerosis Society

    Professor Hiroaki Ogata

  4. PTH variability is associated with increased risk of mortality in Japanese hemodialysis patients

    Article • Clinical and Experimental Nephrology, October 2025, Springer Science + Business Media

    Professor Hiroaki Ogata

  5. Integration of early clinical exposure into curriculum enhances self-assessment of professional competencies in medical practice

    Article • BMC Medical Education, August 2025, Springer Science + Business Media

    Professor Hiroaki Ogata

  6. Association of serum phosphate levels and statin use with cardiovascular events in Japanese patients on chronic haemodialysis: a post-hoc analysis of the LANDMARK trial

    Article • Clinical Kidney Journal, May 2025, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  7. Phosphate binder pill burden and cardiovascular events in patients undergoing hemodialysis

    Article • Therapeutic Apheresis and Dialysis, March 2025, Wiley

    Professor Hiroaki Ogata

  8. The role of glial cells missing 2 in induced pluripotent stem cell parathyroid differentiation

    Article • Tissue and Cell, February 2025, Elsevier

    Professor Hiroaki Ogata

  9. Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

    Article • Therapeutic Apheresis and Dialysis, March 2024, Wiley

    Professor Hiroaki Ogata

  10. Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease

    Article • Journal of Atherosclerosis and Thrombosis, January 2024, Japan Atherosclerosis Society

    Professor Hiroaki Ogata

  11. Effect of renin–angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

    Article • Therapeutic Apheresis and Dialysis, November 2023, Wiley

    Professor Hiroaki Ogata

  12. The Induction of Parathyroid Cell Differentiation from Human Induced Pluripotent Stem Cells Promoted Via TGF-α/EGFR Signaling

    Article • Stem Cells and Development, November 2023, Mary Ann Liebert Inc

    Professor Hiroaki Ogata

  13. Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis—A post hoc analysis of the LANDMARK study

    Article • Therapeutic Apheresis and Dialysis, December 2022, Wiley

    Professor Hiroaki Ogata

  14. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial

    Article • Clinical and Experimental Nephrology, September 2022, Springer Science + Business Media

    Professor Hiroaki Ogata

  15. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles

    Article • Expert Opinion on Drug Safety, February 2022, Taylor & Francis

    Professor Hiroaki Ogata

  16. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis

    Article • JAMA, May 2021, American Medical Association (AMA)

    Professor Hiroaki Ogata

  17. Osteoblastic differentiation of bone marrow mesenchymal stem cells in uremic rats

    Article • Biochemical and Biophysical Research Communications, October 2020, Elsevier

    Professor Hiroaki Ogata

  18. Lower soluble Klotho levels in the pretransplant period are associated with an increased risk of renal function decline in renal transplant patients

    Article • Therapeutic Apheresis and Dialysis, September 2020, Wiley

    Professor Hiroaki Ogata

  19. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial

    Article • Nephrology Dialysis Transplantation, September 2020, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  20. Early response of the parathyroid gland to withdrawal of a calcimimetic compound in uremic rats

    Article • AJP Renal Physiology, March 2020, American Physiological Society

    Professor Hiroaki Ogata

  21. Cdc42 regulates cranial suture morphogenesis and ossification

    Article • Biochemical and Biophysical Research Communications, April 2019, Elsevier

    Professor Hiroaki Ogata

  22. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment

    Article • Therapeutic Apheresis and Dialysis, December 2018, Wiley

    Professor Hiroaki Ogata

  23. Nephronectin Expression is Inhibited by Inorganic Phosphate in Osteoblasts

    Article • Calcified Tissue International, October 2018, Springer Science + Business Media

    Professor Hiroaki Ogata

  24. Cooperation of Rho family proteins Rac1 and Cdc42 in cartilage development and calcified tissue formation

    Article • Biochemical and Biophysical Research Communications, June 2018, Elsevier

    Professor Hiroaki Ogata

  25. FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways

    Article • FEBS Open Bio, April 2018, Wiley

    Professor Hiroaki Ogata

  26. IL-1β suppresses nephronectin expression in osteoblasts via ERK1/2 and JNK

    Article • Biochemical and Biophysical Research Communications, November 2017, Elsevier

    Professor Hiroaki Ogata

  27. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study

    Article • Clinical and Experimental Nephrology, September 2017, Springer Science + Business Media

    Professor Hiroaki Ogata

  28. RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan

    Article • Therapeutic Apheresis and Dialysis, August 2017, Wiley

    Professor Hiroaki Ogata

  29. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study

    Article • Clinical and Experimental Nephrology, July 2017, Springer Science + Business Media

    Professor Hiroaki Ogata

  30. The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study

    Article • Clinical and Experimental Nephrology, May 2017, Springer Science + Business Media

    Professor Hiroaki Ogata

  31. Cardiac effect of vitamin D receptor modulators in uremic rats

    Article • The Journal of Steroid Biochemistry and Molecular Biology, October 2016, Elsevier

    Professor Hiroaki Ogata

  32. What are the Newer Applications for Therapeutic Apheresis in Nephrology?

    Article • Seminars in Dialysis, July 2016, Wiley

    Professor Hiroaki Ogata

  33. Design and baseline characteristics of the LANDMARK study

    Article • Clinical and Experimental Nephrology, July 2016, Springer Science + Business Media

    Professor Hiroaki Ogata

  34. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

    Article • Hypertension Research, January 2016, Springer Science + Business Media

    Professor Hiroaki Ogata

  35. Myocardial SPECT Images in Incident Hemodialysis Patients Without Ischemic Heart Disease

    Article • Therapeutic Apheresis and Dialysis, September 2015, Wiley

    Professor Hiroaki Ogata

  36. False-positive Results Obtained for Immunoglobulin M Antibody Tests of Cerebrospinal Fluid for Herpes Simplex Virus in a Patient with Varicella Zoster Virus Encephalitis

    Article • Internal Medicine, January 2015, Japanese Society of Internal Medicine

    Professor Hiroaki Ogata

  37. Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Refractory Adult-onset Still's Disease

    Article • Internal Medicine, January 2015, Japanese Society of Internal Medicine

    Professor Hiroaki Ogata

  38. Preface

    Article • Therapeutic Apheresis and Dialysis, June 2014, Wiley

    Professor Hiroaki Ogata

  39. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients – a randomized study

    Article • International Journal of Clinical Pharmacology and Therapeutics, May 2014, Dustri-Verlgag Dr. Karl Feistle

    Professor Hiroaki Ogata

  40. Clinical Uses of 22-Oxacalcitriol

    Article • Current Vascular Pharmacology, April 2014, Bentham Science Publishers

    Professor Hiroaki Ogata

  41. Intravenous Phosphate Loading Increases Fibroblast Growth Factor 23 in Uremic Rats

    Article • PLOS One, March 2014, PLOS

    Professor Hiroaki Ogata

  42. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL

    Article • Clinica Chimica Acta, March 2014, Elsevier

    Professor Hiroaki Ogata

  43. Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats

    Article • Clinical and Experimental Nephrology, June 2013, Springer Science + Business Media

    Professor Hiroaki Ogata

  44. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy

    Article • Clinical and Experimental Nephrology, July 2012, Springer Science + Business Media

    Professor Hiroaki Ogata

  45. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF- 

    Article • Nephrology Dialysis Transplantation, January 2012, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  46. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism

    Article • Clinical and Experimental Nephrology, October 2011, Springer Science + Business Media

    Professor Hiroaki Ogata

  47. Correlation between Ischaemia-Modified Albumin and Intermediate-Density Lipoprotein in Haemodialysis Patients with End-Stage Renal Disease

    Article • Journal of International Medical Research, August 2011, SAGE Publications

    Professor Hiroaki Ogata

  48. Involvement of Matrix Metalloproteinase-2 in the Development of Medial Layer Vascular Calcification in Uremic Rats

    Article • Therapeutic Apheresis and Dialysis, May 2011, Wiley

    Professor Hiroaki Ogata

  49. Effects of Calcimimetic Combined with an Angiotensin-Converting Enzyme Inhibitor on Uremic Cardiomyopathy Progression

    Article • American Journal of Nephrology, January 2011, Karger Publishers

    Professor Hiroaki Ogata

  50. Detection of Peripheral Artery Disease by Duplex Ultrasonography among Hemodialysis Patients

    Article • Clinical Journal of the American Society of Nephrology, August 2010, American Society of Nephrology

    Professor Hiroaki Ogata

  51. Involvement of Alpha-Klotho and Fibroblast Growth Factor Receptor in the Development of Secondary Hyperparathyroidism

    Article • American Journal of Nephrology, January 2010, Karger Publishers

    Professor Hiroaki Ogata

  52. Elastin Degradation Accelerates Phosphate-Induced Mineralization of Vascular Smooth Muscle Cells

    Article • Calcified Tissue International, October 2009, Springer Science + Business Media

    Professor Hiroaki Ogata

  53. Vitamin D and vascular calcification in chronic kidney disease

    Article • Bone, July 2009, Elsevier

    Professor Hiroaki Ogata

  54. The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis

    Article • Clinica Chimica Acta, April 2009, Elsevier

    Professor Hiroaki Ogata

  55. Clinical significance of parathyroid intervention on CKD-MBD management

    Article • Clinical Kidney Journal, July 2008, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  56. CKD-MBD: impact on management of kidney disease

    Article • Clinical and Experimental Nephrology, December 2007, Springer Science + Business Media

    Professor Hiroaki Ogata

  57. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells

    Article • Biochemical and Biophysical Research Communications, October 2007, Elsevier

    Professor Hiroaki Ogata

  58. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients

    Article • Clinica Chimica Acta, September 2007, Elsevier

    Professor Hiroaki Ogata

  59. Effects of 22-Oxacalcitriol and Calcitriol on PTH Secretion and Bone Mineral Metabolism in a Crossover Trial in Hemodialysis Patients With Secondary Hyperparathyroidism

    Article • Therapeutic Apheresis and Dialysis, June 2007, Wiley

    Professor Hiroaki Ogata

  60. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: Correlation with low molecular AGE adduct clearance

    Article • Clinica Chimica Acta, February 2007, Elsevier

    Professor Hiroaki Ogata

  61. High free serum acrolein levels in bacterial infection and other disease states associated with oxidative stress: a potential biomarker?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2007, De Gruyter

    Professor Hiroaki Ogata

  62. Therapeutic Strategies for Secondary Hyperparathyroidism in Dialysis Patients

    Article • Therapeutic Apheresis and Dialysis, August 2006, Wiley

    Professor Hiroaki Ogata

  63. Cystic β2-microglobulin amyloidoma in a patient on long-term hemodialysis

    Article • Clinical and Experimental Nephrology, June 2006, Springer Science + Business Media

    Professor Hiroaki Ogata

  64. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism

    Article • Nephrology Dialysis Transplantation, December 2005, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  65. Combination Therapy with Sevelamer Hydrochloride and Calcium Carbonate in Japanese Patients with Long-Term Hemodialysis: Alternative Approach for Optimal Mineral Management

    Article • Therapeutic Apheresis and Dialysis, February 2005, Wiley

    Professor Hiroaki Ogata

  66. Dose-response Study of 22-Oxacalcitriol in Patients with Secondary Hyperparathyroidism

    Article • Therapeutic Apheresis and Dialysis, December 2004, Wiley

    Professor Hiroaki Ogata

  67. Calcimimetic Compound Upregulates Decreased Calcium-Sensing Receptor Expression Level in Parathyroid Glands of Rats with Chronic Renal Insufficiency

    Article • Journal of the American Society of Nephrology, October 2004, American Society of Nephrology

    Professor Hiroaki Ogata

  68. Management of secondary hyperparathyroidism of dialysis patients

    Article • Nephrology, October 2003, Wiley

    Professor Hiroaki Ogata

  69. Beneficial Effects of Calcimimetics on Progression of Renal Failure and Cardiovascular Risk Factors

    Article • Journal of the American Society of Nephrology, April 2003, American Society of Nephrology

    Professor Hiroaki Ogata

  70. New strategies for the treatment of secondary hyperparathyroidism

    Article • American Journal of Kidney Diseases, March 2003, Elsevier

    Professor Hiroaki Ogata

  71. Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models

    Article • Nephrology Dialysis Transplantation, January 2003, Oxford University Press (OUP)

    Professor Hiroaki Ogata

  72. Cigarette smoke condensate aggravates renal injury in the renal ablation model

    Article • Kidney International, June 2002, Elsevier

    Professor Hiroaki Ogata

  73. Clinical Effect of Intravenous Calcitriol Administration on Secondary Hyperparathyroidism

    Article • January 2002, Karger Publishers

    Professor Hiroaki Ogata

  74. Effect of Plasma Exchange on Refractory Hemophagocytic Syndrome Complicated with Myelodysplastic Syndrome

    Article • Therapeutic Apheresis and Dialysis, November 1999, Wiley

    Professor Hiroaki Ogata

  75. Plasma Exchange for Acquired Hemophilia: A Case Report

    Article • Therapeutic Apheresis and Dialysis, November 1999, Wiley

    Professor Hiroaki Ogata